PAH: Risk Reduction Strategies Using Single and Combination Therapies

Released On
March 30, 2022

Expires On
March 29, 2023

Media Type

Completion Time
75 minutes

Cardiology, Primary Care, Pulmonology

Cardiovascular Disease, Heart, Heart Disease, Pulmonary Arterial Hypertension, Respiratory

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by The France Foundation.


This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for pulmonologists, cardiologists, primary care providers, and other health care providers who manage patients with PAH.

Program Overview

This activity will cover how to develop an effective clinical risk-reduction strategy with single or combined drugs for patients with PAH.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Develop an effective clinical risk-reduction strategy with single or combined drugs for patients with PAH
  • Review the evidence for initiating combination therapy in patients with PAH
  • Review current and emerging treatment options for patients with PAH
  • Align treatment strategy to risk level using single or combined drug therapies for patients with PAH
  • Discuss strategies to effectively identify side effects, optimize therapy, and improve outcomes for patients with PAH
  • Apply patient-specific considerations to individualize care for patients with PAH



Estefania Oliveros, MD, MSc

Director of Research in Pulmonary Hypertension
Assistant Professor of Medicine
Lewis Katz School of Medicine
Temple University
Philadelphia, PA


James R. Klinger, MD

Director of the Rhode Island Hospital Pulmonary Hypertension Center
Professor of Medicine
The Warren Alpert Medical School of Brown University
East Providence, RI


Neal Chaisson, MD

Program Director of the Critical Care Medicine Fellowship in the Respiratory Institute
Assistant Professor of Medicine
Cleveland Clinic
Cleveland, OH


Kristin Highland, MD MSCR

Pulmonologist/Critical Care and Rheumatologist
Cleveland Clinic
Cleveland, OH


C. Nicole Swiner, MD

Family Physician at Durham Family Medicine
Physician Speaker with Physician Speaking by KevinMD
Durham, NC

Physician Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

The France Foundation designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The following faculty report that they have no relevant financial relationships to disclose:
  • Estefania Oliveros, MD, MSc
  • James R. Klinger, MD
  • C. Nicole Swiner, MD
The following faculty report that they have relevant financial relationships to disclose:
  • Neal Chaisson, MD, has done non-CE consulting for Guidepoint Health, Galbraith Wight, Putnam Associates, Schlesinger Associates, Gl Local, Athenum American College of Physicians, United Therapeutics, Bayer Healthcare, and Acceleron Pharma. He has served on a speaker’s bureau for Bayer and United Therapeutics.
  • Kristin Highland, MD, has done non-CE consulting for Acceleron Pharmaceuticals, Boehringer Ingelheim, United Therapeutics, Viela Bio, and Forsee. She has served on a speaker’s bureau for Acceleron Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim, Janseen/Johnson and Johnson, and United Therapeutics. She has done contract research for Acceleron Pharmaceuticals, Boehringer Ingelheim, Gossamer Bio, Reata Pharmaceuticals, United Therapeutics, and Viela Bio.

Instructions for Participation and Credit

  1. There are no fees for participating in and receiving credit for this activity
  2. Review the activity objectives and CME/CE information
  3. Complete the CME/CE activity
  4. Complete the CME/CE evaluation/attestation form. This form provides learners with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and their views on future educational needs.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/E certificate will be available for download

Certificates will be emailed to the participant.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

The France Foundation (TFF) requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.


TFF presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF and the commercial supporter(s) assume no liability for the information herein.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or